I believe all patients should be treated with compassion, along with an individualized plan for their treatment and care utilizing a multidisciplinary team approach. We approach each of our patients with the philosophy of "What would you want done for your loved one?" (Quote from Cornelius "Skip" Granai, III, M.D.)

Gynecologic oncology is a unique subspecialty that provides for the participation in all parts of a patient's care. The opportunity to be involved in such a personal experience during a patient's life -- from the time of diagnosis through surgery to managing chemotherapy and participating in all aspects of a woman's care -- is an honor and privilege.

My areas of expertise include robotic surgery for ovarian, endometrial and cervical malignancies, as well as sentinel lymph node mapping for endometrial, cervical and vulvar malignancies, and ovarian cancer biomarker research for the early detection and management of ovarian cancer.

Conditions I Treat:

- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Endometrial cancer
- Cervical cancer
- Vaginal cancer
- Vulvar cancer

Certified Specialties

Gynecologic Oncology - American Board of Obstetrics & Gynecology

Obstetrics & Gynecology - American Board of Obstetrics & Gynecology

Faculty Appointments

Professor - Department of Obstetrics and Gynecology (SMD)

Credentials

Residency & Fellowship

Fellowship, Gynecologic Oncology, Brown University School of Medicine. 1999 - 2002

Residency, Internship/Residency, Eastern Virginia Medical School. 1994 - 1997

Internship, Obstetrics & Gynecology, Eastern Virginia Medical School. 1993 - 1994

Education

MD | University of Alberta School of Medicine (Canada). 1993

Awards

Consumer's Research Council of America. 2015

Rhode Island Monthly Journal, 2014. 2014

New England Association of Gynecologic Oncologists. 2014 - 2014

Rhode Island Monthly Journal, 2013. 2013

Consumer's Research Council of America. 2013

AACC's Outstanding Speaker Award for 2013. 2013

Consumer's Research Council of America. 2012

Rhode Island Monthly Journal, 2012. 2012

Consumer's Research Council of America. 2011

Providence Business News Innovation Awards 2011. 2011

Time Magazine: Top ten Medical Breakthroughs for 2010. 2010

New England Association of Gynecologic Oncologists. 2008

Full Time Faculty Excellence in Teaching Award. 2008

Teaching Award from Chief Residents: Full Time Faculty. 2008

SGO Clinical Practice Science Poster Award. 2007 - 2007

2006 Outstanding faculty mentorship award; from the resident graduating class of 2006. 2006

Medical Student Teaching Award. 2006

New England Association of Gynecologic Oncology. 2005

New England Association of Gynecologic Oncologists. 2002

The American Association of Gynecologic Laparoscopists Award. 1997

Society of Assisted Reproductive Medicine Award. 1996

Gynecologic Oncology Resident Award. 1996

Administrative Chief Resident. 1996 - 1997

Resident of the Year. 1996 - 1997

Research

Clinical Trials

UGYO17017: Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Lead Researcher: Richard G Moore

The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk...

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

Lead Researcher: Richard G Moore

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time dur...

NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Lead Researcher: Richard G Moore

This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lower...

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Lead Researcher: Richard G Moore

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgic...

Patents

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 02, 2021

Patent #: 3128996

Country: Europe

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: May 29, 2018

Patent #: 9,982,010

Country: United States

Inventors: Richard G Moore, Rakesh K Singh

Therapy for Malignant Disease Comprising the Inhibition of Human Epididymal Secretory Protein E4 and Immune Checkpoint Inhibitors

Issue date: December 14, 2021

Patent #: 2,981,068

Country: Canada

Inventors: Richard G Moore, Rakesh K Singh, Naohiro Yano

Therapy for Malignant Disease

Issue date: August 13, 2019

Patent #: 10,376,535

Country: United States

Inventors: Richard G Moore, Rakesh K Singh, Naohiro Yano

Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers

Issue date: December 09, 2020

Patent #: 3311165

Country: Europe

Inventors: Richard G Moore, Rakesh K Singh

7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 16, 2020

Patent #: 10,683,324

Country: United States

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 15, 2021

Patent #: 11,034,719

Country: United States

Inventors: Richard G Moore, Rakesh K Singh

Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers

Issue date: December 09, 2020

Patent #: FR3311165

Country: France

Inventors: Richard G Moore, Rakesh K Singh

Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers

Issue date: December 09, 2020

Patent #: DE3311165

Country: Germany

Inventors: Richard G Moore, Rakesh K Singh

Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers

Issue date: December 09, 2020

Patent #: GB3311165

Country: United Kingdom

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 02, 2021

Patent #: FR3128996

Country: France

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 02, 2021

Patent #: DE3128996

Country: Germany

Inventors: Richard G Moore, Rakesh K Singh

Novel 7-Dehydrocholesterol Derivatives and Methods Using Same

Issue date: June 02, 2021

Patent #: GB3128996

Country: United Kingdom

Inventors: Richard G Moore, Rakesh K Singh

Publications

Journal Articles

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.

Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2024 October 3 :JCO2400683. Epub 10/03/2024.

Author Correction: AI is a viable alternative to high throughput screening: a 318-target study.

Scientific reports.. 2024 September 1614 (1):21579. Epub 09/16/2024.

Identification of circulating tumor cells captured by the FDA-cleared Parsortix PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations.

Ciccioli M, Kim K, Khazan N, Khoury JD, Cooke MJ, Miller MC, O'Shannessy DJ, Pailhes-Jimenez AS, Moore RG

Journal of experimental & clinical cancer research : CR.. 2024 August 2143 (1):240. Epub 08/21/2024.

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Valabrega G, Pothuri B, Oaknin A, Graybill WS, Sánchez AB, McCormick C, Baurain JF, Tinker AV, Denys H, O'Cearbhaill RE, Hietanen S, Moore RG, Knudsen AØ, de La Motte Rouge T, Heitz F, Levy T, York W, Gupta D, Monk BJ, González-Martín A

Gynecologic oncology.. 2024 August 187 :128-138. Epub 06/03/2024.

Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.

Graybill WS, Pardo Búrdalo B, O'Malley DM, Vergote I, Monk BJ, Auranen A, Copeland LJ, Sabbatini R, Herzog TJ, Follana P, Pothuri B, Braicu EI, McCormick C, Yubero A, Moore RG, Vuylsteke P, Raaschou-Jensen N, York W, Hartman J, González-Martín A

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.. 2024 July 134 (7):1041-1050. Epub 07/01/2024.

In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia.

Sahasrabudhe DM, Liesveld JL, Minhajuddin M, Singh NA, Nath S, Kumar VM, Balys M, Evans AG, Azadniv M, Hansen JN, Becker MW, Sharon A, Thomas VK, Moore RG, Khera MK, Jordan CT, Singh RK

Scientific reports.. 2024 June 414 (1):12868. Epub 06/04/2024.

A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes.

Campbell TM, Campbell EK, Culakova E, Blanchard LM, Wixom N, Guido JJ, Fetten J, Huston A, Shayne M, Janelsins MC, Mustian KM, Moore RG, Peppone LJ

Breast cancer research and treatment.. 2024 June 205 (2):257-266. Epub 03/06/2024.

Normal Risk Ovarian Screening Study: 21-Year Update.

Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, Bedi D, Bedia E, Bevers T, Boruta D, Carlson M, Holman L, Leeds L, Mathews C, McCann G, Moore RG, Schlumbrecht M, Slomovitz B, Tobias D, Williams-Brown Y, Bevers MW, Liu J, Gornet TG, Handy BC, Lu Z, Bedia JS, Skates SJ, Bast RC

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2024 April 142 (10):1102-1109. Epub 01/09/2024.

Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.

Young Han C, Bedia JS, Yang WL, Hawley SJ, Bergan L, Hopper M, Celestino J, Guo J, Gornet TG, Soosaipillai A, Yang H, Doskocil SD, Lokshin AE, Handy BC, Diamandis EP, Moore RG, Lu KH, Lu Z, Anderson KS, Drescher CW, Skates SJ, Bast RC

British journal of cancer.. 2024 March 130 (5):861-868. Epub 01/09/2024.

Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial Cancer.

Kim K, Khazan N, Rowswell-Turner RB, Singh RK, Moore T, Strawderman MS, Miller JP, Snyder CWA, Awada A, Moore RG

Cancers.. 2024 February 2816 (5)Epub 02/28/2024.

Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.

González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ

Future oncology.. 2024 20 (22):1531-1544. Epub 03/19/2024.

A Whole Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Feasibility, Nutrient, and Patient-Reported Outcomes.

Campbell , Campbell TM, Culakova E, Blanchard BLM, Wixom RBN, Guido MJ, Fetten J, Huston A, Shayne M, Janelsins M, Mustian PK, Moore RG, Peppone LJ

Research square.. 2023 November 21 Epub 11/21/2023.

Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1.

Khazan N, Quarato ER, Singh NA, Snyder CWA, Moore T, Miller JP, Yasui M, Teramoto Y, Goto T, Reshi S, Hong J, Zhang N, Pandey D, Srivastava P, Morell A, Kawano H, Kawano Y, Conley T, Sahasrabudhe DM, Yano N, Miyamoto H, Aljitawi O, Liesveld J, Becker MW, Calvi LM, Zhovmer AS, Tabdanov ED, Dokholyan NV, Linehan DC, Hansen JN, Gerber SA, Sharon A, Khera MK, Jurutka PW, Rochel N, Kim KK, Rowswell-Turner RB, Singh RK, Moore RG

Cancers.. 2023 June 3015 (13)Epub 06/30/2023.

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath Iii CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C

The New England journal of medicine.. 2023 June 8388 (23):2159-2170. Epub 03/27/2023.

A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix PC1 System.

Cohen EN, Jayachandran G, Moore RG, Cristofanilli M, Lang JE, Khoury JD, Press MF, Kim KK, Khazan N, Zhang Q, Zhang Y, Kaur P, Guzman R, Miller MC, Reuben JM, Ueno NT

Cancers.. 2022 October 2614 (21)Epub 10/26/2022.

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.

Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 July 140 (19):2138-2147. Epub 03/15/2022.

Evolution and Transformation of Uterine Transplantation: A Systematic Review of Surgical Techniques and Outcomes.

Escandón JM, Bustos VP, Santamaría E, Langstein HN, Ciudad P, Hernandez-Alejandro R, Moore RG, Leckenby JI, Manrique OJ

Journal of reconstructive microsurgery.. 2022 July 38 (6):429-440. Epub 09/17/2021.

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2021 May 1527 (10):2734-2741. Epub 03/25/2021.

HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.

Rowswell-Turner RB, Singh RK, Urh A, Yano N, Kim KK, Khazan N, Pandita R, Sivagnanalingam U, Hovanesian V, James NE, Ribeiro JR, Kadambi S, Linehan DC, Moore RG

The Journal of immunology : official journal of the American Association of Immunologists.. 2021 May 15206 (10):2478-2488. Epub 04/26/2021.

A Surgical Window Trial Evaluating medroxyprogesterone acetate with or without Entinostat in Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Linda Duska; Virginia Filiaci; Joan Walker; Laura Holman; Emily Hill; Richard Moore; Kari Ring; Michael Pearl; Carolyn Muller; Christina Kushnir; Heather Lankes; Megan Samuelson; Kelley Carrick; Anand Rajan; William Rodgers; Elise Kohn; Richard Piekarz; Kimberly Leslie.

Clinical Cancer Research. 2021; .

HE4 Over-expression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.

Rachael Rowswell-Turner; Rakesh Singh; Anze Urh; Naohiro Yano; Kyu Kwang Kim; Ravina Pandita; Umayal Sivagnanalingam; Virginia Hovanesian; Nicole James; Jennifer Ribeiro; Sindhuja Kadambi; David Linehan; Richard Moore.

The Journal of Immunology. 2021; 206: 2478-2488.

Evolution and Transformation of Uterine Transplantation: A Systematic Review of Surgical Techniques and Outcomes.

Escandón JM; Bustos VP; Santamaria E; Langstein HN; Ciudad P; Hernandez-Alejandro R; Moore RG; Leckenby JI; Manrique OJ.

Journal of Reconstructive Microsurgery. 2021; .

Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian 2 cancer and other malignant tumors.

Alexandra Blackman; Jessica Mitchell; Rachael Rowswell-Turner; Rakesh Singh; Kyu Kwang Kim; Elizabeth Eklund; Steven Skates; Robert C. Bast; Geralyn Messerlian; M Craig Miller; Richard G. Moore.

Tumor Biology. 2021; 43(1): 355-365.

Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.

Blackman A, Mitchell J, Rowswell-Turner R, Singh R, Kim KK, Eklund E, Skates S, Bast RC, Messerlian G, Miller MC, Moore RG

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.. 2021 43 (1):355-365. Epub 1900 01 01.

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.

James NE, Emerson JB, Borgstadt AD, Beffa L, Oliver MT, Hovanesian V, Urh A, Singh RK, Rowswell-Turner R, DiSilvestro PA, Ou J, Moore RG, Ribeiro JR

Scientific reports.. 2020 May 2210 (1):8558. Epub 05/22/2020.

Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines.

Kim KK, Singh RK, Khazan N, Kodza A, Singh NA, Jones A, Sivagnanalingam U, Towner M, Itamochi H, Turner R, Moore RG

Scientific reports.. 2020 February 2410 (1):3241. Epub 02/24/2020.

Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines.

Kyu Kwang Kim; Rakesh K. Singh; Negar Khazan; Arif Kodza; Niloy A. Singh; Aaron Jones; Umayal Sivagnanalingam; MaryTowner; Hiroaki Itamochi; Rachael Turner; Richard G. Moore.

Scientific Reports Nature Research:. 2020; 10(3241).

Targeting Vitamin-D receptor (VDR) by a small molecule antagonist MeTC7 inhibits PD-L1 2 but controls THMYCN neuroblastoma growth PD-L1 independently.

Rakesh K. Singh; KyuKwang Kim; Rachael B. Rowswell-Turner; Jeanne N. Hansen; Negar Khazan; Aaron Jones,;Umayal Sivagnanalingam; Yuki Teramoto; Takuro Goto; Ye Jian; Nicholas Battaglia; Thomas Conley; Virginia Hovanesian; Naohiro Yano; Ravina Pandita; Leggy A. Arnold; Russel Hopson; Debasmita Ojha; Ashoke Sharon; John Ashton; Hiroshi Miyamoto; Nina F. Schor; Michael T. Milano; David C. Linehan; Scott A. Gerber; Richard G. Moore.

BioRxiv. 2020; .

Septins disruption controls tumor growth and enhances efficacy of Herceptin.

Rakesh K. Singh; Kyu Kwang Kim; Negar Khazan; Rachael B. Rowswell-Turner; Christian Laggner; Aaron Jones; Priyanka Srivastava; Virginia Hovanesian; Liz Lamere; Thomas Conley; Ravina Pandita; Cameron Baker; Jason R Myers; Elizabeth Pritchett; Awada Ahmad; Luis Ruffolo; Katherine Jackson; Scott A. Gerber; John Ashton; Michael T. Milano; David Linehan; Richard G Moore.

Bibtex. 2020; .

Role of trypsin and protease-activated receptor-2 in ovarian cancer.

Kim KK, Turner R, Khazan N, Kodza A, Jones A, Singh RK, Moore RG

PloS one.. 2020 15 (5):e0232253. Epub 05/04/2020.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ,

The New England journal of medicine.. 2019 December 19381 (25):2391-2402. Epub 09/28/2019.

Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?

Moore RG, Blackman A, Miller MC, Robison K, DiSilvestro PA, Eklund EE, Strongin R, Messerlian G

Gynecologic oncology.. 2019 July 154 (1):150-155. Epub 04/13/2019.

Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer.

Rowswell-Turner RB, Rutishauser JA, Kim KK, Khazan N, Sivagnanalingam U, Jones AM, Singh RK, Moore RG

Translational oncology.. 2019 July 12 (7):917-924. Epub 05/10/2019.

Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins.

James NE, Cantillo E, Yano N, Chichester CO, DiSilvestro PA, Hovanesian V, Rao RSP, Kim KK, Moore RG, Ahsan N, Ribeiro JR

Oncotarget.. 2019 April 2610 (31):2959-2972. Epub 04/26/2019.

Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.

James NE, Oliver MT, Ribeiro JR, Cantillo E, Rowswell-Turner RB, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC

Frontiers in pharmacology.. 2019 10 :216. Epub 03/19/2019.

Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.

Felix AS, Cohn DE, Brasky TM, Zaino R, Park K, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Randall ME, Brinton LA

American journal of obstetrics and gynecology.. 2018 November 219 (5):459.e1-459.e11. Epub 08/07/2018.

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells.

James NE, Cantillo E, Oliver MT, Rowswell-Turner RB, Ribeiro JR, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC

Clinical and experimental immunology.. 2018 September 193 (3):327-340. Epub 1900 01 01.

"Ember Trial: "Evaluation of multiple protein and molecular biomarkers to estimate risk of cancer in gynecology patients presenting with a pelvic mass."

Moore, R.G.; Miller, M.C.; Kim, K.; Sivangnanalingham, U.; DuBeshter, B.; Angel, C.; Thomas, S.G.; Seto, K.; Englert, D.

2018; Supplement 1: 178-179.

Assessment of serum HE4 levels throughout the normal menstrual cycle.

Moore RG, Plante B, Hartnett E, Mitchel J, Raker CA, Vitek W, Eklund E, Lambert-Messerlian G

American journal of obstetrics and gynecology.. 2017 July 217 (1):53.e1-53.e9. Epub 02/22/2017.

Predictors for lymph nodes involvement in low risk endometrial cancer.

Kadan Y, Calvino AS, Katz A, Katz S, Moore RG

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.. 2017 May 37 (4):514-518. Epub 03/24/2017.

Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.

Brasky TM, Felix AS, Cohn DE, McMeekin DS, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Park KJ, Ali S, Brinton LA

Journal of the National Cancer Institute.. 2017 March 1109 (3):1-10. Epub 1900 01 01.

Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer Regulation of the Extracelluar Matrix.

Ribeiro JR, Gaudet HM, Khan M, Schorl C, James NE, Oliver MT, DiSilvestro PA, Moore RG, Yano N

Frontiers in oncology.. 2017 7 :332. Epub 01/22/2018.

Levels of antimüllerian hormone in serum during the normal menstrual cycle.

Lambert-Messerlian G, Plante B, Eklund EE, Raker C, Moore RG

Fertility and sterility.. 2016 January 105 (1):208-13.e1. Epub 10/23/2015.

Templated polymers enable selective capture and release of lysophosphatidic acid in human plasma via optimization of non-covalent binding to functional monomers.

Wang J, Sibrian-Vazquez M, Escobedo JO, Wang L, Chu YH, Moore RG, Strongin RM

The Analyst.. 2015 November 21140 (22):7572-7. Epub 1900 01 01.

Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.

Kim KK, Han A, Yano N, Ribeiro JR, Lokich E, Singh RK, Moore RG

Scientific reports.. 2015 November 165 :15911. Epub 11/16/2015.

Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.

Lokich E, Palisoul M, Romano N, Craig Miller M, Robison K, Stuckey A, DiSilvestro P, Mathews C, Granai CO, Lambert-Messerlian G, Moore RG

Gynecologic oncology.. 2015 November 139 (2):248-52. Epub 09/11/2015.

Antitumor Activity of 3-Indolylmethanamines 31B and PS121912.

Guthrie ML, Sidhu PS, Hill EK, Horan TC, Nandhikonda P, Teske KA, Yuan NY, Sidorko M, Rodali R, Cook JM, Han L, Silvaggi NR, Bikle DD, Moore RG, Singh RK, Arnold LA

Anticancer research.. 2015 November 35 (11):6001-7. Epub 1900 01 01.

Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1? in cancer cells.

Kim KK, Abelman S, Yano N, Ribeiro JR, Singh RK, Tipping M, Moore RG

Scientific reports.. 2015 October 155 :14296. Epub 10/15/2015.

Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.

Felix AS, Scott McMeekin D, Mutch D, Walker JL, Creasman WT, Cohn DE, Ali S, Moore RG, Downs LS, Ioffe OB, Park KJ, Sherman ME, Brinton LA

Gynecologic oncology.. 2015 October 139 (1):70-6. Epub 09/01/2015.

Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.

Felix AS, Brinton LA, McMeekin DS, Creasman WT, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino R, Sherman ME

Journal of the National Cancer Institute.. 2015 September 107 (9)Epub 06/18/2015.

The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.

Wang Y, Han A, Chen E, Singh RK, Chichester CO, Moore RG, Singh AP, Vorsa N

International journal of oncology.. 2015 May 46 (5):1924-34. Epub 03/17/2015.

Predictive factors for the presence of malignant transformation of pelvic endometriosis.

Kadan Y, Fiascone S, McCourt C, Raker C, Granai CO, Steinhoff M, Moore RG

European journal of obstetrics, gynecology, and reproductive biology.. 2015 February 185 :23-7. Epub 12/02/2014.

Spiroguanidine rhodamines as fluorogenic probes for lysophosphatidic acid.

Wang L, Sibrian-Vazquez M, Escobedo JO, Wang J, Moore RG, Strongin RM

Chemical communications : Chem comm. 2015 January 3151 (9):1697-700. Epub 1900 01 01.

Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer.

Moore RG, Hawkins DM, Miller MC, Landrum LM, Gajewski W, Ball JJ, Allard WJ, Skates SJ

Gynecologic oncology.. 2014 December 135 (3):547-51. Epub 10/23/2014.

A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.

Krivak TC, Lele S, Richard S, Secord AA, Leath CA, Brower SL, Tian C, Moore RG

American journal of obstetrics and gynecology.. 2014 July 211 (1):68.e1-8. Epub 02/12/2014.

HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation.

Lokich E, Singh RK, Han A, Romano N, Yano N, Kim K, Moore RG

Scientific reports.. 2014 June 304 :5500. Epub 06/30/2014.

Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone.

Robison K, Roque D, McCourt C, Stuckey A, DiSilvestro PA, Sung CJ, Steinhoff M, Granai CO, Moore RG

Gynecologic oncology.. 2014 June 133 (3):416-20. Epub 03/11/2014.

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.

Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK

Scientific reports.. 2014 January 64 :3574. Epub 01/06/2014.

Pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer: Is there a role for prolonged therapy?

Cronin B, Robison K, Raker C, Moore RG, Granai C.O., Dizon DS.

Clinical Ovarian and Other Gynecologic Cancer. 2014; : 17-20.

Simple enrichment and analysis of plasma lysophosphatidic acids.

Wang J, Sibrian-Vazquez M, Escobedo JO, Lowry M, Wang L, Chu YH, Moore RG, Strongin RM

The Analyst.. 2013 November 21138 (22):6852-9. Epub 1900 01 01.

A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer.

Rutherford T, Orr J, Grendys E, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ

Gynecologic oncology.. 2013 November 131 (2):362-7. Epub 08/13/2013.

PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models.

Kawar N, Maclaughlan S, Horan TC, Uzun A, Lange TS, Kim KK, Hopson R, Singh AP, Sidhu PS, Glass KA, Shaw S, Padbury JF, Vorsa N, Arnold LA, Moore RG, Brard L, Singh RK

Genes & cancer.. 2013 November 4 (11-12):524-34. Epub 1900 01 01.

Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino R

Gynecologic oncology.. 2013 May 129 (2):277-84. Epub 02/26/2013.

A two stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early stage incident cancers and demonstrates high positive predictive value.

Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore RG, Granai CO, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun C, Horick N, Fritsche H, Bast RC.

Cancer. 2013; 119(19): 3454-3461.

Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines.

Horan TC, Zompa MA, Seto CT, Kim KK, Moore RG, Lange TS

Investigational new drugs.. 2012 August 30 (4):1460-70. Epub 08/02/2011.

7 Methyl indole ethyl isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells.

Kristjansdottir K, Kim K, Choi JS, Horan TC, Brard L, Moore RG, Singh RK

Gynecologic oncology.. 2012 August 126 (2):252-8. Epub 05/02/2012.

The presence and location of epithelial implants and implants with epithelial proliferation may predict a higher risk of recurrence in serous borderline ovarian tumors: a clinicopathologic study of 188 cases.

Quddus MR, Sung CJ, Zhang C, Moore RG, Ou JJ, Steinhoff MM, Lawrence WD

Human pathology.. 2012 May 43 (5):747-52. Epub 11/01/2011.

Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.

Bast RC, Skates S, Lokshin A, Moore RG

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.. 2012 May 22 Suppl 1 (Suppl 1):S5-8. Epub 1900 01 01.

Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.

Kim KK, Lange TS, Singh RK, Brard L, Moore RG

BMC cancer.. 2012 April 1312 :147. Epub 04/13/2012.

Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC

American journal of obstetrics and gynecology.. 2012 April 206 (4):351.e1-8. Epub 12/30/2011.

Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G

American journal of obstetrics and gynecology.. 2012 April 206 (4):349.e1-7. Epub 12/30/2011.

Vulvar encapsulated solid papillary carcinoma with neuroendocrine differentiation: a case report.

Zhang C, Quddus MR, Sung CJ, Moore RG, Lawrence WD

International journal of surgical pathology.. 2012 February 20 (1):97-100. Epub 03/21/2011.

Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells.

Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS, Moore RG

International journal of oncology.. 2012 January 40 (1):227-35. Epub 09/12/2011.

Cytotoxic properties of Adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cells.

Lange TS, Horan TC, Kim KK, Singh AP, Vorsa N, Brard L, Moore RG, Singh RK

Chemical biology & drug design.. 2012 January 79 (1):92-103. Epub 11/04/2011.

Purified cranberry proanthocyanidines (PAC-1A) cause pro-apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells.

Singh AP, Lange TS, Kim KK, Brard L, Horan T, Moore RG, Vorsa N, Singh RK

International journal of oncology.. 2012 January 40 (1):99-108. Epub 10/06/2011.

Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.

Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK

PloS one.. 2012 7 (4):e34443. Epub 04/03/2012.

Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.

Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK

Gynecologic oncology.. 2011 November 123 (2):370-8. Epub 07/30/2011.

Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus.

Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.. 2011 October 21 (7):1185-90. Epub 1900 01 01.

Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.

Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, Skates SJ

Obstetrics and gynecology.. 2011 August 118 (2 Pt 1):280-288. Epub 1900 01 01.

Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.

Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG

Gynecologic oncology.. 2011 July 122 (1):183-9. Epub 05/06/2011.

Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation.

Kim KK, Singh RK, Strongin RM, Moore RG, Brard L, Lange TS

PloS one.. 2011 April 296 (4):e19049. Epub 04/29/2011.

Breast cancer: pursuing state-of-the-art care. Foreword.

Orr JW, Moore RG

Clinical obstetrics and gynecology.. 2011 March 54 (1):83-4. Epub 1900 01 01.

Breast development and anatomy.

Pandya S, Moore RG

Clinical obstetrics and gynecology.. 2011 March 54 (1):91-5. Epub 1900 01 01.

Update on sentinel lymph node evaluation in gynecologic malignancies.

Robison K, Holman LL, Moore RG

Current opinion in obstetrics & gynecology.. 2011 February 23 (1):8-12. Epub 1900 01 01.

Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ

American journal of obstetrics and gynecology.. 2010 September 203 (3):228.e1-6. Epub 05/14/2010.

Current clinical use of biomarkers for epithelial ovarian cancer.

Moore RG, Maclaughlan S

Current opinion in oncology.. 2010 September 22 (5):492-7. Epub 1900 01 01.

Current state of biomarker development for clinical application in epithelial ovarian cancer.

Moore RG, MacLaughlan S, Bast RC

Gynecologic oncology.. 2010 February 116 (2):240-5. Epub 10/31/2009.

In vitro maturation of oocytes via the pre-fabricated self-assembled artificial human ovary.

Krotz SP, Robins JC, Ferruccio TM, Moore RG, Steinhoff MM, Morgan JR, Carson S.

Journal of Assisted Reproductive Genetics. 2010; 27(12): 743-750.

A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation.

Clements A, Robison K, Granai C, Steinhoff MM, Scalia-Wilbur J, Moore RG

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.. 2009 December 19 (9):1591-4. Epub 1900 01 01.

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ

Gynecologic oncology.. 2009 January 112 (1):40-6. Epub 10/12/2008.

Recurrent thigh abscess with necrotizing fasciitis from a retained transobturator sling segment.

Rardin CR, Moore RG, Ward RM, Myers DL.

Journal of Minimally Invasive Gynecology. 2009; 16(1): 84-87.

The novel biomarker HE4 improves the sensitivity of CA125 alone for monitoring and differential diagnosis of ovarian cancer.

Allard JW and Moore RG.

Clinical Laboratories International. 2009; 3: 20-21.

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC, Lu K

Gynecologic oncology.. 2008 August 110 (2):196-201. Epub 05/21/2008.

Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial.

Moore RG, Robison K, Brown AK, DiSilvestro P, Steinhoff M, Noto R, Brard L, Granai CO

Gynecologic oncology.. 2008 April 109 (1):65-70. Epub 02/05/2008.

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC

Gynecologic oncology.. 2008 February 108 (2):402-8. Epub 12/03/2007.

The utility of immunohistochemical staining for detection of metastatic disease in sentinel lymph nodes. Invited editorial

Moore RG, Robison K, Steinhoff M.

Gynecologic Oncology. 2008; 111(1): 159.

How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above.

Moore RG, Bast RC

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2007 September 2025 (27):4159-61. Epub 08/13/2007.

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC

Gynecologic oncology.. 2007 September 106 (3):490-7. Epub 05/25/2007.

Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer.

Gordinier ME, Dizon DS, Weitzen S, Disilvestro PA, Moore RG, Granai CO

Journal of palliative medicine.. 2007 February 10 (1):61-6. Epub 1900 01 01.

Lower uterine segment involvement as a predictor for lymph node spread in endometrial carcinoma.

Madom LM, Brown AK, Lui F, Moore RG, Granai CO, DiSilvestro PA.

Gynecologic Oncology. 2007; 107(1): 75-78.

The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients.

Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, Moore RG, Granai CO

Gynecologic oncology.. 2006 October 103 (1):176-80. Epub 03/27/2006.

Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes.

Robison K, Steinhoff MM, Granai CO, Brard L, Gajewski W, Moore RG

Gynecologic oncology.. 2006 April 101 (1):24-7. Epub 10/24/2005.

Two more for Good Measure: Six versus Eight Cycles of Carboplatin and Paclitaxel as Adjuvant Treatment for Epithelial Ovarian Cancer.

Dizon DS, Weitzen S, Rojan A, Schwartz J, Miller J, DiSilvestro P, Gordinier M, Moore RG, Tejada-Berges T, Pires L, Legare R, Granai C.O..

Gynecologic Oncology. 2006; 100: 417-421.

Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.

Dizon DS, Schwartz J, Rojan A, Miller J, Pires L, DiSilvestro P, Gordinier ME, Moore RG, Granai C.O. and Legare RG.

Gynecologic Oncology. 2006; 100: 149-151.

HPV vaccines--why aren't they the answer yet?

Brown AK, Moore RG

Medicine and health, Rhode Island.. 2005 March 88 (3):74-9. Epub 1900 01 01.

Incidence of metastasis to the ovaries from nongenital tract primary tumors.

Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM

Gynecologic oncology.. 2004 April 93 (1):87-91. Epub 1900 01 01.

Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining.

Moore RG, Granai CO, Gajewski W, Gordinier M, Steinhoff MM

Gynecologic oncology.. 2003 November 91 (2):378-82. Epub 1900 01 01.

Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva.

Moore RG, DePasquale SE, Steinhoff MM, Gajewski W, Steller M, Noto R, Falkenberry S

Gynecologic oncology.. 2003 June 89 (3):475-9. Epub 1900 01 01.

Vulvar epithelioid sarcoma in pregnancy.

Moore RG, Steinhoff MM, Granai CO, DeMars LR

Gynecologic oncology.. 2002 April 85 (1):218-22. Epub 1900 01 01.

Metacognitive awareness and prevention of relapse in depression: empirical evidence.

Teasdale JD, Moore RG, Hayhurst H, Pope M, Williams S, Segal ZV

Journal of consulting and clinical psychology.. 2002 April 70 (2):275-87. Epub 1900 01 01.

HE4 expression predicts CD8+ tumor infiltrating lymphocytes (TILs) and PD-L1 status in Epithelial Ovarian Cancer

Urh A, Romano N, Kim KK, Ribeiro J, Raker C, Yano N, Hovanessian G, Schorl C, Singh R, Moore RG.

Scientific Reports, Nature. .

Septins disruption controls tumor growth and enhances efficacy of Herceptin

Rakesh K Singh; Kyu Kwang Kim; Negar Khazan; Rachael B. Rowswell-Turner; Christian Laggner; Aaron Jones; Priyanka Srivastava; Virginia Hovanesian; Liz Lamere; Thomas Conley; Ravina Pandita; Cameron Baker; Jason R Myers; Elizabeth Pritchett; Awada Ahmad; Luis Ruffolo; Katherine Jackson; Scott A. Gerber; John Ashton; Michael T. Milano; David Linehan; Richard G Moore.

BioRxIV. .

Olaparib with or without Cediranib versus Platinum-based Chemotherapy in Recurrent Platinum-sensitive Ovarian Cancer (NRG Oncology GY004): A Randomized, Open-Label, Phase 3 Trial (NCT02446600)

Joyce F. Liu; Mark F. Brady; Ursula A. Matulonis; Austin Miller; Elise C. Kohn; Elizabeth M. Swisher; David Cella; William P. Tew; Noelle G. Cloven; Carolyn Y Muller; David P. Bender; Richard G. Moore; David P. Michelin; Steven E. Waggoner; Melissa A. Geller; Keiichi Fujiwara; Stacy D. D'Andre; Michael Carney; Angeles A. Secord; Katherine M. Moxley; Michael A. Bookman.

Journal of Clinical Oncology. .

Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass.

Reid Shaw; Anna E. Lokshin; M. Craig Miller; Geralyn Messerlian-Lambert; Richard G. Moore.

Cancers. .

Books

Clinical Obstetrics and Gynecology, (2011)

Chapter: Forward

Authors: James W. Orr and Richard G. Moore

Publisher: Wolters Kluwer / Lippincott Williams & Wilkins 2011

Clinical Obstetrics and Gynecology (2011)

Chapter: Breast Development and Anatomy

Authors: Sonali Pandya and Richard G. Moore

Publisher: Wolters Kluwer / Lippincott Williams & Wilkins 2011

Precis Gynecology (2011)

Chapter: Management of Ovarian Cysts and Adnexal Masses

Authors: Richard G. Moore and Shannon MacLaughlan

Publisher: Precis: Gynecology 2011

Ovarian Cancer: State of the Art (2009)

Chapter: Biomarkers and ovarian cancer

Authors: Richard G. Moore and Robert Bast, Jr.

Publisher: Remedica Medical Education and Publishing 2009

OBGYN in Review (2006)

Chapter: Abnormal Cervical Cytology

Authors: Paul DiSilvestro & Richard G. Moore.

Publisher: OBGYN in Review 2006

OBGYN in Review (2006)

Chapter: Post-Operative Care and Complications

Authors: Richard G. Moore & Paul DiSilvestro.

Publisher: OBGYN 2006

Biomedical Communications (2006)

Chapter: Diseases and abnormalities of the vulva, vagina and adjacent epithelial sites

Authors: Wright CV, Bryson P, Collado CM, Guijon F, Indman P, McKinney CD, Mercado LC, Moore RG, Powell JL, Rojas TS, Shier RM.

Publisher: Biomedical Communications 2006

Pier.acponline.org (2003)

Chapter: Endometrial cancer, PIER Module

Authors: Moore RG, Steller MA

Publisher: American college of physicians 2003

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

4.8

During this visit, did this provider show respect for what you had to say?

4.9

During this visit did this provider give you easy to understand information about these health questions or concerns?

4.8

During this visit, did this provider listen carefully to you?

4.8

During this visit, did this provider explain things in a way that was easy to understand?

4.8

Patient Comments

Dr. Moore was very friendly. He explained the causes of my problem so I would better understand it and he also explained what some of the options would be pending the results of my MRI. This was my first time being seen in this office and I was very satisfied with how I was treated and how friendly and helpful everyone was.

Aug 17, 2024

Lovely and genuinely.

Aug 05, 2024

Very good

Aug 03, 2024

Dr. Moore , nurses and Np's are the best I've seen yet ! I can't give enough praises for their care . I've felt included in my care at a difficult time i. Their consistent care in meeting my needs since diagnosis ! I can't give enough praise to this office !

Jul 31, 2024

Dr Moore was wonderful. He really cares about his patients. He had different options for my treatment and I get to make the final decision.

Jul 23, 2024

5.0

Everything was excellent

Jun 30, 2024

5.0

He forgot to mention item that appeared on my ultra sound. He apologized when he came in while I was speaking with his nurse.

Jun 15, 2024

2.6

Dr. Moore presents with condescending presentation. I felt like he was giving me a rhetorical "pat on the head" when talking with me. [...]

Jun 07, 2024

5.0

I was just overall impressed with the 1-1 approach that was evident here, and which is lacking in so many other offices where a majority of time is spent looking at a screen instead of the patient.

Jun 03, 2024

5.0

Very informative and educational. 100% listened to my questions/concerns.

Jun 03, 2024

5.0

Very caring

Apr 26, 2024

5.0

Dr. Moore explained everything clearly and made me feel at ease. He has a good sense of humor also.

Apr 23, 2024

5.0

Dr. Moore put me at ease right away. I came in anxious and worried, and I left feeling like I had a plan going forward, and I was in good hands. My anxiety was greatly reduced by the time I left. I can't say enough good things about these providers. [...] This physician is a breath of fresh air.

Mar 30, 2024

5.0

Dr. Moore was very kind, gentle and patient.

Mar 03, 2024

5.0

Dr. R. Moore was very nice and answered all my questions and made me understand my condition and what the plans are to make things better. He eased my fears and to me that is very important.

Feb 10, 2024

3.8

Dr. Moore is excellent.

Jan 13, 2024

5.0

Dr. Moore was wonderful! He gave clear explanations, took time to make sure we understood everything, and answered all of our questions. He had a calm and welcoming manner, which put me at ease. He was knowledgable about my health issues. He was kind and caring and that is very important.

Dec 29, 2023

5.0

Dr. Moore has the best bed side manner. He cares deeply about his patients. The minute I met him. I knew I was going to be OK.

Dec 14, 2023

5.0

Very happy

Dec 08, 2023

5.0

Dr listened to me and was very caring. Made me feel like he was going to make sure I was going to be ok.

Dec 02, 2023

5.0

We were very pleased with Dr. Moore

Nov 28, 2023

3.4

Didn't really answer my concerns about what I was still experiencing from current surgery. Only focused on what surgery option to perform next.

Nov 11, 2023

5.0

Provider was very comforting

Nov 02, 2023

5.0

Time was taken to make sure that I understand my procedure.

Sep 14, 2023

5.0

Dr Moore is phenomenal

Aug 07, 2023

5.0

Dr. Moore & staff are professional & cured my cancer.

Jul 18, 2023

5.0

Dr. Moore and his staff listen and then explain things to the patient.

Jul 10, 2023

5.0

Best experience I have ever had in a doctor's office. My providers are very good and I am not unhappy but, this experience was better. My husband was with me and he commented on how great it was too

May 13, 2023

5.0

Dr Moore was, as I had been assured by his nursing staff, very calm, patient and confident. This did indeed calm my nerves.

May 09, 2023

5.0

Highest regard for this doctor and everyone that has been taking care of me for the past three years.

Apr 25, 2023

5.0

Dr. Moore is the best!

Apr 25, 2023

3.0

I feel he could have been more in depth

Mar 18, 2023

5.0

I have complete confidence in Dr. Moore. He is an amazing Dr. He explains everything thoroughly and has a wonderful bedside manner.

Mar 15, 2023

1.0

[...] The provider was fair in answering questions. [...]

Mar 14, 2023

5.0

I was immediately put at ease with this provider and trusted him without hesitation.

Mar 02, 2023

5.0

Dr. Explained thoroughly statistics and why I would need some radiation.

Feb 03, 2023

5.0

Excellent provider. Highly skilled, kind, caring, attentive. Offered clear explanations of options, and if surgical plan.

Jan 29, 2023

5.0

The oncology dept. is one of the best departments on everything.

Dec 28, 2022

5.0

Great Team! Professional, Friendly, Knowledgeable, Caring!

Dec 24, 2022

5.0

I feel very confident with Dr. Moore.

Dec 14, 2022

3.0

Facing more surgery and or radiation and chemo, just felt it was matter of fact

Nov 25, 2022

5.0

Dr. Moore is a wonder doctor!

Nov 15, 2022

5.0

Always listens and considers my input

Nov 14, 2022

5.0

Doctor explains everything and listens to questions and understands if you have worries. He's a very caring person.

Oct 18, 2022

5.0

Once again, SO much better than any care I've ever had locally (I came from Utica for the appointment).

Sep 30, 2022

3.5

He is a very good doctor. I like him very much he is friendly and easy to talk to.

Sep 29, 2022

5.0

My interactions with this care provider were very positive.

Sep 28, 2022

5.0

Dr. Richard Moore is an excellent surgeon who is extremely personable.

Sep 23, 2022

Dr. Moore shows great kindness and concern.

Sep 09, 2022

5.0

I would not wish uterine cancer on anyone, but I cannot say enough about the care I have received from Dr. Moore and the team at that office.

Aug 25, 2022

1.8

Dr. Moore is excellent Dr. [...]

Aug 25, 2022

5.0

I've already recommended Dr. Moore to a few friends and colleagues

Aug 20, 2022

5.0

Dr Moore is so knowledgeable and is determined to achieve the best outcome for me, and answers my concerns with good information and care.

Aug 05, 2022

5.0

I will recommend Dr. Moore to anyone needing Dr. Moore's care.

Jul 27, 2022

3.5

Always listens and gives appropriate and clear answers and explanations to my concerns

Jun 22, 2022

5.0

Dr. Moore was very thorough with all answers and explanations. Also had a very comforting reassuring demeanor.

Jun 10, 2022

4.6

Very knowledgeable physician.

May 17, 2022

5.0

I have absolute confidence in this office.

May 11, 2022

5.0

I can't say enough about Dr. Moore - he was excellent!

Apr 29, 2022

5.0

Dr Moore has so much concern for me. He shows so much empathy for what I'm going through with cancer. He listens to me and lets me cry if I feel I need to he's right there with me! I don't feel like I'm rushed out of the visit so he can keep his schedule on track. He has been a great support for me and wouldn't want any other doctor

Apr 22, 2022

5.0

Dr Moore is wonderful and I couldn't be happier having him for my cancer primary care doctor. He even told me about errors in my previous diagnosis nine years ago. Very enlightening. I appreciate that so much.

Apr 20, 2022

5.0

Excellent experience.

Apr 15, 2022

5.0

Waiting is not a problem because I am given all the time necessary for my concerns and condition and I expect to wait as the provider gives the same time needed to other cancer patients

Apr 13, 2022

5.0

Dr. Moore is intelligent & compassionate. Don't know how I would make it through my very serious illness without him.

Apr 13, 2022

4.6

Provider shows emotional intelligence which is key. [...]

Apr 11, 2022

5.0

Very good experience

Mar 31, 2022

5.0

I am so thoroughly impressed with Dr Moore and his associates. One of the best and nicest doctors that I have encountered.

Mar 25, 2022

5.0

Dr Moore was very professional but did show me that he really cared how scared I was. By the end of my visit he made me feel much more relaxed

Feb 17, 2022

5.0

Hespends enough time with me [...]

Feb 12, 2022